BioMarin Pharmaceutical (NASDAQ:BMRN) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) in a report issued on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $110.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for BioMarin Pharmaceutical’s FY2024 earnings at $2.05 EPS. BMRN has been the topic […]
More Stories
Sax Wealth Advisors LLC Buys 314 Shares of AbbVie Inc. (NYSE:ABBV)
Sax Wealth Advisors LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.7% in the...
Eliot Finkel Investment Counsel LLC Sells 115 Shares of McDonald’s Co. (NYSE:MCD)
Eliot Finkel Investment Counsel LLC decreased its position in McDonald’s Co. (NYSE:MCD – Free Report) by 0.5% in the 3rd...
Blue Trust Inc. Boosts Holdings in McDonald’s Co. (NYSE:MCD)
Blue Trust Inc. lifted its position in shares of McDonald’s Co. (NYSE:MCD – Free Report) by 34.1% in the third...
Lumia (LUMIA) Trading Down 4.3% Over Last 7 Days
Lumia (LUMIA) traded down 13% against the US dollar during the 24-hour period ending at 19:00 PM E.T. on October...
Saltmarble (SML) Price Hits $0.46
Saltmarble (SML) traded flat against the dollar during the 24-hour period ending at 19:00 PM ET on October 19th. During...
Basic Attention Token (BAT) Price Tops $0.18
Basic Attention Token (BAT) traded up 1.7% against the US dollar during the twenty-four hour period ending at 19:00 PM...